Europe Genomic Cancer Panel and Profiling Market: Analysis and Forecast, 2023-2033
This report will be delivered in 3-5 working days.
Introduction to Europe Genomic Cancer Panel and Profiling Market
As of 2023, the Europe genomic cancer panel and profiling market was valued at $2.64 billion and is expected to attain a value of $6.50 billion in 2033. The market is anticipated to grow at a CAGR of 9.42% during the forecast period 2023-2033. This growth is being driven by advances in genomic research and an increasing emphasis on precision therapy in oncology.
Market Introduction
Genomic cancer panels and profiling are a contemporary technique to cancer detection that examines the genetic characteristics of malignancies before symptoms occur. The capacity of these panels to provide extensive genetic insights facilitates early detection and the development of tailored treatment strategies, which is a considerable advantage. The genomic cancer panel and profiling market is expanding because to the transformational potential these technologies have for changing cancer management. These panels improve our understanding of cancer genetics by allowing healthcare providers to identify particular genetic changes and customize interventions accordingly.
In the European market, genetic cancer panels and profiling are gaining popularity for cancer screening and management. These modern technologies provide detailed genetic information about malignancies, allowing for early detection and individualized treatment regimens. The demand for these panels is increasing as a result of their transformational potential in changing cancer management. Factors driving market expansion in Europe include the growing popularity of liquid biopsy testing, increased cancer risk due to lifestyle changes, and the need for early detection.
Market Segmentation
Segmentation 1: by Application
Product/Innovation Strategy: The Europe genomic cancer panel and profiling market has been extensively segmented based on various categories, such as application, end user, and country. This can help readers get a clear overview of the segments accounting for the largest share and the ones that are well-positioned to grow in the coming years.
Introduction to Europe Genomic Cancer Panel and Profiling Market
As of 2023, the Europe genomic cancer panel and profiling market was valued at $2.64 billion and is expected to attain a value of $6.50 billion in 2033. The market is anticipated to grow at a CAGR of 9.42% during the forecast period 2023-2033. This growth is being driven by advances in genomic research and an increasing emphasis on precision therapy in oncology.
Market Introduction
Genomic cancer panels and profiling are a contemporary technique to cancer detection that examines the genetic characteristics of malignancies before symptoms occur. The capacity of these panels to provide extensive genetic insights facilitates early detection and the development of tailored treatment strategies, which is a considerable advantage. The genomic cancer panel and profiling market is expanding because to the transformational potential these technologies have for changing cancer management. These panels improve our understanding of cancer genetics by allowing healthcare providers to identify particular genetic changes and customize interventions accordingly.
In the European market, genetic cancer panels and profiling are gaining popularity for cancer screening and management. These modern technologies provide detailed genetic information about malignancies, allowing for early detection and individualized treatment regimens. The demand for these panels is increasing as a result of their transformational potential in changing cancer management. Factors driving market expansion in Europe include the growing popularity of liquid biopsy testing, increased cancer risk due to lifestyle changes, and the need for early detection.
Market Segmentation
Segmentation 1: by Application
- Clinical
- Research
- Hospitals
- Clinical and Diagnostic Laboratories
- Research and Academic Institutes
- Other End Users
- U.K.
- France
- Italy
- Germany
- Spain
Product/Innovation Strategy: The Europe genomic cancer panel and profiling market has been extensively segmented based on various categories, such as application, end user, and country. This can help readers get a clear overview of the segments accounting for the largest share and the ones that are well-positioned to grow in the coming years.
Executive Summary
1 MARKETS
1.1 Market Scope
1.1.1 Key Questions Answered in this Report
1.2 Research Methodology
1.2.1 Genomic Cancer Panel and Profiling Market: Research Methodology
1.2.2 Data Sources
1.2.3 Market Estimation Model
1.2.4 Criteria for Company Profiling
1.3 Market Overview
1.3.1 Market Definition
1.3.2 Market Footprint and Growth Potential
1.3.3 Future Potential
2 INDUSTRY ANALYSIS
2.1 Legal Requirements
2.1.1 Regulation of Genetic Tests
2.1.2 NCCN Guidelines
2.1.3 Reimbursement Scenario
2.2 Patent Analysis
2.2.1 Patent Filing Trend
2.2.2 Patent Analysis (by Year)
2.2.3 Patent Analysis (by Country)
3 MARKET DYNAMICS
3.1 Overview
3.1.1 Impact Analysis
3.2 Market Drivers
3.2.1 Rising Need for Cancer Profiling in Developed Countries Driving Demand for Genomic Panels and Profiling Tests
3.2.2 Increase in Genomic Research Funding Expanding the Market for Genomic Cancer Panels and Profiling
3.2.3 Technological Advancements in the Field of Informatics Expanding Consumer Reach
3.3 Market Restraints
3.3.1 Significant Implications of Reimbursement Reductions Impacting Growth of the Genomic Cancer Panel and Profiling Market
3.3.2 Impact of High-Cost Pressure Hindering Development in Genomic Cancer Panel and Profiling Testing
3.4 Market Opportunities
3.4.1 Robust Pipeline of Genomic Cancer Panels and Profiling Tests Poised to Revolutionize Cancer Diagnosis
3.4.2 Discovery of New Biomarkers Presents an Opportunity for the Development of Diagnostics Tools and Technologies
4 COMPETITIVE INSIGHTS
4.1 Overview
4.2 Key Strategies and Developments
4.2.1 Product Launches, Approvals, and Upgradations
4.2.2 Synergistic Activities
4.2.3 Mergers and Acquisitions
4.2.4 Business Expansions, Funding, and Licenses
4.3 Growth-Share Analysis
4.3.1 Growth-Share Analysis (by Technology), 2022
5 BY REGION
5.1 Overview
5.2 Europe
5.2.1 Key Dynamics
5.2.2 Germany
5.2.3 France
5.2.4 U.K.
5.2.5 Italy
5.2.6 Spain
5.2.7 Rest-of-Europe
6 COMPANY PROFILES
6.1 Overview
6.2 F. Hoffmann-La Roche Ltd
6.2.1 Company Overview
6.2.2 Role of F. Hoffmann-La Roche Ltd in the Genomic Cancer Panel and Profiling Market
6.2.3 Corporate Strategies
6.2.4 Business Strategies
6.2.5 Financials
6.2.6 Analyst Perspective
1 MARKETS
1.1 Market Scope
1.1.1 Key Questions Answered in this Report
1.2 Research Methodology
1.2.1 Genomic Cancer Panel and Profiling Market: Research Methodology
1.2.2 Data Sources
1.2.3 Market Estimation Model
1.2.4 Criteria for Company Profiling
1.3 Market Overview
1.3.1 Market Definition
1.3.2 Market Footprint and Growth Potential
1.3.3 Future Potential
2 INDUSTRY ANALYSIS
2.1 Legal Requirements
2.1.1 Regulation of Genetic Tests
2.1.2 NCCN Guidelines
2.1.3 Reimbursement Scenario
2.2 Patent Analysis
2.2.1 Patent Filing Trend
2.2.2 Patent Analysis (by Year)
2.2.3 Patent Analysis (by Country)
3 MARKET DYNAMICS
3.1 Overview
3.1.1 Impact Analysis
3.2 Market Drivers
3.2.1 Rising Need for Cancer Profiling in Developed Countries Driving Demand for Genomic Panels and Profiling Tests
3.2.2 Increase in Genomic Research Funding Expanding the Market for Genomic Cancer Panels and Profiling
3.2.3 Technological Advancements in the Field of Informatics Expanding Consumer Reach
3.3 Market Restraints
3.3.1 Significant Implications of Reimbursement Reductions Impacting Growth of the Genomic Cancer Panel and Profiling Market
3.3.2 Impact of High-Cost Pressure Hindering Development in Genomic Cancer Panel and Profiling Testing
3.4 Market Opportunities
3.4.1 Robust Pipeline of Genomic Cancer Panels and Profiling Tests Poised to Revolutionize Cancer Diagnosis
3.4.2 Discovery of New Biomarkers Presents an Opportunity for the Development of Diagnostics Tools and Technologies
4 COMPETITIVE INSIGHTS
4.1 Overview
4.2 Key Strategies and Developments
4.2.1 Product Launches, Approvals, and Upgradations
4.2.2 Synergistic Activities
4.2.3 Mergers and Acquisitions
4.2.4 Business Expansions, Funding, and Licenses
4.3 Growth-Share Analysis
4.3.1 Growth-Share Analysis (by Technology), 2022
5 BY REGION
5.1 Overview
5.2 Europe
5.2.1 Key Dynamics
5.2.2 Germany
5.2.3 France
5.2.4 U.K.
5.2.5 Italy
5.2.6 Spain
5.2.7 Rest-of-Europe
6 COMPANY PROFILES
6.1 Overview
6.2 F. Hoffmann-La Roche Ltd
6.2.1 Company Overview
6.2.2 Role of F. Hoffmann-La Roche Ltd in the Genomic Cancer Panel and Profiling Market
6.2.3 Corporate Strategies
6.2.4 Business Strategies
6.2.5 Financials
6.2.6 Analyst Perspective
LIST OF FIGURES
Figure 1: Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 2: Genomic Cancer Panel and Profiling Market (by Application), % Share, 2022 and 2033
Figure 3: Genomic Cancer Panel and Profiling Market (by End User), % Share 2022 and 2033
Figure 4: Genomic Cancer Panel and Profiling Market Snapshot (by Region), $Billion, 2022
Figure 5: Genomic Cancer Panel and Profiling Market: Research Methodology
Figure 6: Primary Research Methodology
Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
Figure 8: Top-Down Approach (Segment-Wise Analysis)
Figure 9: Genomic Cancer Panel and Profiling Workflow, End User Perspective
Figure 10: Genomic Cancer Panel and Profiling Workflow, Laboratory Technician Perspective
Figure 11: Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 12: General Testing Criterion According to the NCCN Guidelines
Figure 13: Reimbursement Components in the U.S.
Figure 14: Genomic Cancer Panel and Profiling Market, Patent Analysis (by Year), January 2020-October 2023
Figure 15: Genomic Cancer Panel and Profiling Market, Patent Analysis (by Country), January 2020-October 2023
Figure 16: Genomic Cancer Panel and Profiling Market Dynamics
Figure 17: Cancer Profiling Cases in Developed Countries
Figure 18: Share of Global Cancer Prevalence, 2010-2019
Figure 19: Share of Global Age-Standardized Death Rate of Cancer, 2010-2019
Figure 20: Genomic Research Funding by National Human Genome Research Institute (NHGRI), $Million, 2020, 2021, and 2022
Figure 21: Key Players Offering
Figure 22: Reimbursement Reductions Adopted for Oncology Testing as per PAMA Revisions
Figure 23: Cost Difference between the Multi-Gene Panel Test and Usual Care Screening Test
Figure 24: Share of Key Developments, January 2020-October 2023
Figure 25: Number of Product Launches, Approvals, and Upgradations (by Company), January 2020-October 2023
Figure 26: Growth-Share Analysis of the Genomic Cancer Panel and Profiling Market (by Technology), 2022
Figure 27: Genomic Cancer Panel and Profiling Market Snapshot (by Region), $Billion, 2022
Figure 28: Europe Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 29: Europe Genomic Cancer Panel and Profiling Market (by Application), $Million, 2022-2033
Figure 30: Europe Genomic Cancer Panel and Profiling Market (by End User), $Million, 2022-2033
Figure 31: Europe Genomic Cancer Panel and Profiling Market (by Country), $Billion, 2022-2033
Figure 32: Germany Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 33: France Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 34: U.K. Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 35: Italy Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 36: Spain Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 37: Rest-of-Europe Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 38: Genomic Cancer Panel and Profiling Market, Total Number of Companies Profiled
Figure 39: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 40: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
Figure 41: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
Figure 42: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022
Figure 1: Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 2: Genomic Cancer Panel and Profiling Market (by Application), % Share, 2022 and 2033
Figure 3: Genomic Cancer Panel and Profiling Market (by End User), % Share 2022 and 2033
Figure 4: Genomic Cancer Panel and Profiling Market Snapshot (by Region), $Billion, 2022
Figure 5: Genomic Cancer Panel and Profiling Market: Research Methodology
Figure 6: Primary Research Methodology
Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
Figure 8: Top-Down Approach (Segment-Wise Analysis)
Figure 9: Genomic Cancer Panel and Profiling Workflow, End User Perspective
Figure 10: Genomic Cancer Panel and Profiling Workflow, Laboratory Technician Perspective
Figure 11: Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 12: General Testing Criterion According to the NCCN Guidelines
Figure 13: Reimbursement Components in the U.S.
Figure 14: Genomic Cancer Panel and Profiling Market, Patent Analysis (by Year), January 2020-October 2023
Figure 15: Genomic Cancer Panel and Profiling Market, Patent Analysis (by Country), January 2020-October 2023
Figure 16: Genomic Cancer Panel and Profiling Market Dynamics
Figure 17: Cancer Profiling Cases in Developed Countries
Figure 18: Share of Global Cancer Prevalence, 2010-2019
Figure 19: Share of Global Age-Standardized Death Rate of Cancer, 2010-2019
Figure 20: Genomic Research Funding by National Human Genome Research Institute (NHGRI), $Million, 2020, 2021, and 2022
Figure 21: Key Players Offering
Figure 22: Reimbursement Reductions Adopted for Oncology Testing as per PAMA Revisions
Figure 23: Cost Difference between the Multi-Gene Panel Test and Usual Care Screening Test
Figure 24: Share of Key Developments, January 2020-October 2023
Figure 25: Number of Product Launches, Approvals, and Upgradations (by Company), January 2020-October 2023
Figure 26: Growth-Share Analysis of the Genomic Cancer Panel and Profiling Market (by Technology), 2022
Figure 27: Genomic Cancer Panel and Profiling Market Snapshot (by Region), $Billion, 2022
Figure 28: Europe Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 29: Europe Genomic Cancer Panel and Profiling Market (by Application), $Million, 2022-2033
Figure 30: Europe Genomic Cancer Panel and Profiling Market (by End User), $Million, 2022-2033
Figure 31: Europe Genomic Cancer Panel and Profiling Market (by Country), $Billion, 2022-2033
Figure 32: Germany Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 33: France Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 34: U.K. Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 35: Italy Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 36: Spain Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 37: Rest-of-Europe Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 38: Genomic Cancer Panel and Profiling Market, Total Number of Companies Profiled
Figure 39: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 40: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
Figure 41: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
Figure 42: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022
LIST OF TABLES
Table 1: Genomic Cancer Panel and Profiling Market, Impact Analysis
Table 2: Technological Trends in the Genomic Cancer Panel and Profiling Market
Table 3: Genomic Cancer Panel and Profiling Market, Impact Analysis
Table 4: Genomic Cancer Panel and Profiling Market, Pipeline Tests
Table 5: Ongoing Cancer-Based Biomarkers Trials
Table 6: Europe Genomic Cancer Panel and Profiling Market, Impact Analysis
Table 1: Genomic Cancer Panel and Profiling Market, Impact Analysis
Table 2: Technological Trends in the Genomic Cancer Panel and Profiling Market
Table 3: Genomic Cancer Panel and Profiling Market, Impact Analysis
Table 4: Genomic Cancer Panel and Profiling Market, Pipeline Tests
Table 5: Ongoing Cancer-Based Biomarkers Trials
Table 6: Europe Genomic Cancer Panel and Profiling Market, Impact Analysis
